RxDoctor Payments Data

Kevin Ladin, MD

Physical Medicine & Rehabilitation · Phoenix, AZNPI 1396748851

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,926 of the $2,702 with a category attached, or 71.3%. 15 manufacturers reported payments, led by Medtronic at 35.8% of the total. Reporting peaked in 2019 at $1,039 and has fallen 64.2% since, to $372 in 2025.

$2,702in general payments, 2019–2025

Across 126 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$968
  • AbbVie$854
  • Protega Pharmaceutials Inc$209
  • Electronic Waveform Lab, Inc.$208
  • Boston Scientific$101
  • IBSA Pharma Inc.$76
  • plus $286 from 9 others

What the payments were for

  • Travel & lodging$77529%
  • Food & beverage$1,92671%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,702 in reported general payments places this provider in the 80th percentile of 162 physical medicine & rehabilitation providers in Arizona.

See all physical medicine & rehabilitation providers in Arizona

Medicare billing

Part B allowed, 2024
$28,859
Medicare patients
61
Services billed
268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl19$14,243
Xtampza ErOxycodone Myristate12$6,320
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen111$4,914
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen127$4,114
Oxycodone Hcl182$3,221
Gabapentin109$2,433
Morphine Sulfate ErMorphine Sulfate65$2,126
Metaxalone14$1,875
Morphine Sulfate37$1,817
Fentanyl12$1,679
Tramadol Hcl63$783
Pregabalin29$743
Cyclobenzaprine Hcl39$412
Baclofen28$299
Duloxetine Hcl16$208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$72$6,32012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 162 physical medicine & rehabilitation providers in Arizona.

Other physical medicine & rehabilitation in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →